EA200600931A1 - Антитело против igf-i-рецептора - Google Patents

Антитело против igf-i-рецептора

Info

Publication number
EA200600931A1
EA200600931A1 EA200600931A EA200600931A EA200600931A1 EA 200600931 A1 EA200600931 A1 EA 200600931A1 EA 200600931 A EA200600931 A EA 200600931A EA 200600931 A EA200600931 A EA 200600931A EA 200600931 A1 EA200600931 A1 EA 200600931A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
igf
receptor
antibodies
tumors
Prior art date
Application number
EA200600931A
Other languages
English (en)
Other versions
EA009807B1 (ru
Inventor
Раджиева Сингх
Дэниэл Дж. Таварес
Ненси И. Дагдайгиен
Original Assignee
Иммьюноджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Иммьюноджен, Инк. filed Critical Иммьюноджен, Инк.
Publication of EA200600931A1 publication Critical patent/EA200600931A1/ru
Publication of EA009807B1 publication Critical patent/EA009807B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Антитела, гуманизированные антитела, имеющие перестроенную поверхность антитела, фрагменты антител, дериватизованные антитела и их конъюгаты с цитотоксическими агентами, которые специфически связываются с рецептором инсулин-подобного фактора роста I и ингибируют его, противодействуют действиям IGF-I, IGF-II и сыворотки на рост и выживание опухолевых клеток и которые по существу лишены агонистической активности. Эти антитела и их фрагменты могут быть использованы, необязательно вместе с другими терапевтическими агентами, в лечении опухолей, которые экспрессируют повышенные уровни IGF-I-рецептора, таких как рак молочной железы, рак ободочной кишки, рак легкого, рак яичника, синовиальная саркома, рак предстательной железы, рак поджелудочной железы, и эти дериватизованные антитела могут быть использованы в диагностике и визиографии опухолей, которые экспрессируют повышенные уровни IGF-I-рецептора.
EA200600931A 2003-12-08 2004-12-07 Антитело против igf-i-рецептора EA009807B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (2)

Publication Number Publication Date
EA200600931A1 true EA200600931A1 (ru) 2006-10-27
EA009807B1 EA009807B1 (ru) 2008-04-28

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600931A EA009807B1 (ru) 2003-12-08 2004-12-07 Антитело против igf-i-рецептора

Country Status (13)

Country Link
EP (1) EP1692176A4 (ru)
JP (1) JP2008502589A (ru)
KR (1) KR20070001883A (ru)
CN (1) CN1886424A (ru)
AU (1) AU2004303792A1 (ru)
BR (1) BRPI0417406A (ru)
CA (1) CA2548065A1 (ru)
CR (1) CR8426A (ru)
EA (1) EA009807B1 (ru)
EC (1) ECSP066595A (ru)
IL (1) IL174770A0 (ru)
MX (1) MXPA06005540A (ru)
NO (1) NO20063155L (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055699A1 (en) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190067275A (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532685A (ja) * 1998-12-04 2002-10-02 ノバルティス アクチエンゲゼルシャフト 活性化ビトロネクチンレセプターαＶβ３をターゲティングするために有用な方法および組成物
EP1399483B1 (en) * 2001-01-05 2010-04-14 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055699A1 (en) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
US9353366B2 (en) 2011-10-10 2016-05-31 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence

Also Published As

Publication number Publication date
AU2004303792A1 (en) 2005-07-07
CA2548065A1 (en) 2005-07-07
KR20070001883A (ko) 2007-01-04
ECSP066595A (es) 2006-10-17
CN1886424A (zh) 2006-12-27
NO20063155L (no) 2006-08-11
EP1692176A1 (en) 2006-08-23
IL174770A0 (en) 2006-08-20
EP1692176A4 (en) 2008-11-12
EA009807B1 (ru) 2008-04-28
MXPA06005540A (es) 2006-08-17
JP2008502589A (ja) 2008-01-31
CR8426A (es) 2007-12-04
BRPI0417406A (pt) 2007-04-03

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
MX2013011363A (es) Anticuerpos para peptidos citosolicos.
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
EA200601405A1 (ru) Гуманизированное антитело
ECSP066595A (es) Anticuerpo del receptor anti-igf-i
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006078892A3 (en) Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
UA93875C2 (ru) Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125)
TN2013000387A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
TH125460B (th) แอนทาโกนิสต์แอนติบอดีสำหรับการรักษามะเร็ง
TH125460A (th) แอนทาโกนิสต์แอนติบอดีสำหรับการรักษามะเร็ง

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU